Drug intelligence / Profile preview

SGA302A

Development stage: Preclinical
Lead developer: BMG Pharma
Administration: Subcutaneous

Overview

SGA302A is an injectable subdermal booster currently in the preclinical stage of development by BMG Pharma. Designed for applications in aesthetic medicine, the product is formulated as a filler or skin quality enhancer intended for administration into the subdermal layer. It is part of BMG Pharma's pipeline of innovative aesthetic solutions, which typically leverage proprietary formulation technologies to improve skin hydration, structural integrity, and overall appearance. As a subdermal booster, it likely functions by providing physical volume and promoting skin rejuvenation through localized delivery of active ingredients or structural polymers.

Other names: SGA302A Booster SubdermisSGA-302A Booster SubdermisSGA 302A Booster Subdermis

Beyond the preview

Go deeper on SGA302A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGA302A.

Explore the full profile